


Nemonoxacin malate

Cat. No.:	HY-111023
CAS No.:	951163-60-3
Molecular Formula:	C ₂₄ H ₃₁ N ₃ O ₉
Molecular Weight:	505.52
Target:	Antibiotic; Bacterial
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (197.82 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.9782 mL	9.8908 mL	19.7816 mL
		5 mM		0.3956 mL	1.9782 mL	3.9563 mL
10 mM		0.1978 mL	0.9891 mL	1.9782 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant <i>Streptococcus pneumoniae</i> and (HY-121544) Methicillin -resistant <i>Staphylococcus aureus</i> . Nemonoxacin malate can be used for the research of community-acquired pneumonia ^{[1][2]} .
IC₅₀ & Target	Quinolone
In Vitro	Nemonoxacin has antibacterial activity against <i>Chlamydia pneumoniae</i> with MIC ₉₀ s of 0.06 µg/mL ^[1] . Nemonoxacin has highly active against community-acquired MRSA (CA-MRSA) (MIC ₉₀ : 0.5 and 0.06 µg/ml), and exerts limited

activity against (HY-B0356) [Ciprofloxacin](#)-resistant MRSA (MIC₉₀: 1 µg/ml), and (HY-B0671) [Vancomycin](#)-intermediate MRSA (MIC₉₀: 2 µg/ml)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chotikanatis K, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58(3):1800-1.

[2]. Lai CC, et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2014 Apr;12(4):401-17.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA